Pipeline
Core Global Development Pipeline of ONO
Oncology
As of 24 Oct, 2024
| Product Name | Mechanism | Target Disease | Development Stage | Country / Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Filing | Approval | |||||
| ONO-4059 | BTK inhibitor | Primary central nervous system lymphoma | JP・KR・TW | In-house | |||||
| US | |||||||||
| Waldenström macroglobulinemia/Lymphoplasmacytic lymphoma | JP | ||||||||
| ONO-7475 | Axl/Mer inhibitor | Pancreatic cancer ★ | JP | In-house | |||||
| EGFR mutation-positive non-small cell lung cancer | JP | ||||||||
| ONO-4685 | PD-1 x CD3 bispecific antibody | T-cell lymphoma | JP・US | In-house | |||||
| ONO-4578 | PG receptor (EP4) antagonist | Gastric cancer ★ | JP・KR・TW | In-house | |||||
| Colorectal cancer ★ | JP | ||||||||
| Pancreatic cancer ★ | JP | ||||||||
| Non-small cell lung cancer ★ | JP | ||||||||
| Hormone receptor-positive, HER2-negative breast cancer | JP | ||||||||
| ONO-7914 | STING agonist | Solid tumor ★ | JP | In-house | |||||
| ONO-7018 | MALT1 Inhibitor | Non-Hodgkin lymphoma, Chronic lymphocytic leukemia | JP・US | Chordia | |||||
| ONO-8250 | iPSC-derived HER2 CAR T-cell therapy | HER2-expressing Solid tumor | US | Fate | |||||
★Combination with Nivolumab
Other than oncology
As of 24 Oct, 2024
| Product Name | Mechanism | Target Disease | Development Stage | Country / Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Filing | Approval | |||||
| ONO-4059 | BTK inhibitor | Pemphigus | JP | In-house | |||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Chemotherapy-Induced Peripheral Neuropathy | JP | In-house | |||||
| ONO-2808 | S1P5 receptor agonist | Multiple System Atrophy | JP・US | In-house | |||||
| ONO-4685 | PD-1 x CD3 bispecific antibody | Autoimmune disease | JP・EU | In-house | |||||
| ONO-2020 | Epigenetic Regulation | Neurodegenerative disease | US | In-house | |||||
| ONO-1110 | Endocannabinoid regulation | Pain | JP | In-house | |||||
| ONO-4915 | PD-1 x CD19 bispecific antibody | Autoimmune disease | JP | In-house | |||||
Deciphera
As of 24 Oct, 2024
| Product Name | Mechanism | Target Disease | Development Stage | Country / Region |
Licensor | ||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | Filing | Approval | |||||
| QINLOCK／ripretinib | KIT inhibitor | GIST 4th | Approved in more then 40 countries | Deciphera | |||||
| GIST 2nd KIT Exon 11+17/18 | NA・SA・EU・AU・KR・TW | Deciphera | |||||||
| DCC-3014／vimseltinib | CSF-1R inhibitor | TGCT* | NA・EU・AU・HK | Deciphera | |||||
| DCC-3116 | ULK inhibitor | Solid tumor（with sotorasib） | US | Deciphera | |||||
| Solid tumor（with ripretinib） | US | Deciphera | |||||||
| DCC-3084 | Pan-RAF inhibitor | Solid tumor | US | Deciphera | |||||
* : FDA, EMA Filing accepted
NA : North America, SA : South America, AU : Australia, SG : Singapore, HK : Hong Kong, KR : Korea, TW : Taiwan, JP : Japan
